This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm.

As my regular readers are aware, I have been involved in Nexium litigation for some time and Chair the American Association for Justice’s (AAJ) Nexium Litigation Group. First, some background on Nexium: Nexium is a proton pump inhibitor (PPI), which is taken to relieve the symptoms of gastroesophageal reflux disorder (GERD), commonly referred to as acid reflux. PPIs, such as Nexium, work by blocking the release of stomach acid.

With the emphasis of my firm on protecting the rights of children and parents harmed by pharmaceutical companies, I am always diligent to keep abreast of pharmacovigilance signals regarding new causes of birth defects. I have had my eye on Nexium birth defects for some time, as pregnant women often experience an increased suffering of GERD, and as a result, many are prescribed a PPI such as Nexium.

Study Links PPIs and Nexium to Birth Defects
The scary news is that prenatal (before birth) use of Nexium and other PPIs by pregnant women have been linked to a doubled risk of cardiac birth defects in their babies. Researchers from the University of Pennsylvania analyzed data from The Health Improvement Network (THIN) to determine that there may be a correlation between PPI use during the first trimester and congenital heart defects.

I will be following this situation closely and am now actively accepting cases of  Nexium birth defects in children born to women taking Nexium during the first trimester. I will also be updating my attorney colleagues on Nexium birth defects at the American Association for Justice’s (AAJ) Winter Convention in Phoenix in February.

If you or someone you know was on Nexium or any proton pump inhibitor given birth to a child with a heart defect and or other birth defects, please contact me directly for a free, no-obligation evaluation of your Nexium birth defect claim.